A New Animal Model of Thrombophilia Confirms that High Plasma Factor VIII Levels Are Thrombogenic

Summary

The thrombotic risk associated with elevated plasma levels of clotting factor VIII (FVIII) was investigated in a mouse model of thrombophilia. After the intravenous injection of recombinant human FVIII and/or of purified FVIII-free human von Willebrand factor (vWF), a controlled mild injury was inflicted on the carotid artery of FVB mice by irradiation with filtered green light in combination with intravenous injection of the dye rose bengal. Formation of a platelet-rich thrombus was continuously monitored for 40 min via transillumination and the thrombus size was measured via image analysis. Administration of recombinant human FVIII at 40 g/kg led to initial FVIII plasma activities equivalent to 250% of normal human plasma FVIII activity and significantly enhanced thrombus size. Immunohistochemical staining illustrated the accumulation of FVIII within the thrombi. Human vWF, even at 10 mg/kg, had no effect on thrombus formation. The thrombotic tendency induced by FVIII was significantly inhibited by the administration of human vWF in a dose-dependent manner. Separate plasma measurements revealed that human FVIII has comparable affinities for human and murine vWF but that human vWF does not effectively bind murine platelets. The inhibition by human vWF of the thrombotic tendency induced by human FVIII could therefore be explained by a lack of accumulation of FVIII within the developing thrombus because of the reduced affinity of human vWF for murine platelets and the reduced occupancy of murine von Willebrand factor by human FVIII after injection of human vWF. These results show that vWF actively participates in FVIII accumulation in the arterial thrombus and provide experimental evidence for epidemiological findings that elevated plasma FVIII levels are associated with an increased thrombotic risk, also in arteries.

• References

• 1 Weiss HJ, Sussman I I, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest 1977; 60: 390-404.
• 2 Kingsbury KJ. Relation of ABO blood-groups to atherosclerosis. Lancet 1971; I: 199-203.
• 3 Talbot S, Ryrie D, Wakley EJ, Langman MJS. ABO blood groups and venous thrombotic disease. Lancet 1970 I 1257-9.
• 4 Medalie JH, Levene C, Papier C, Goldbourt U, Dreyfuss F, Oron D, Neufeld H, Riss E. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. N Engl J Med 1971; 285: 1348-53.
• 5 O'Brien JR. Blood group, von Willebrand's factor and heart disease. Thromb Res 1990; 59: 221.
• 6 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; II: 533-7.
• 7 Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, della Volpe A, Polli E. the PLAT Study group. Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb 1992; 12: 1063-70.
• 8 Rosendaal FR. Factor VIII and coronary heart disease. Eur J Epidemiol 1992; 8: 71-5.
• 9 Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
• 10 O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825-8.
• 11 Wessler S. Studies in intravascular coagulation. I. Coagulation changes in isolated venous segments. J Clin Invest 1952; 31: 1011-4.
• 12 Umemura K, Wada K, Uematsu T, Nakashima M. Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 1993; 24: 1077-81.
• 13 Stockmans F, Stassen JM, Vermylen J, Hoylaerts MF, Nystrom Å. A technique to investigate mural thrombus formation in small arteries and veins: I. Comparative morphometric and histological analysis. Ann Plast Surg 1997; 38: 56-62.
• 14 Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-97.
• 15 Ware J, Russell S, Ruggeri M. Cloning of the murine platelet glycoprotein Ib gene highlighting specieS-specific platelet adhesion. Blood Cells Mol Dis 1997; 23: 292-301.
• 16 Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart diseases. The ARIC Study. Circulation 1997; 96: 1102-8.
• 17 Matsuno H, Uematsu T, Nagashima S, Nakashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods 1991; 25: 303-17.
• 18 Takiguchi Y, Wada K, Nakashima M. Comparison of the inhibitory effects of the TxA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TxA2. Thromb Haemost 1992; 68: 460-3.
• 19 Kaku S, Umemura K, Mizuno A, Yano S, Suzuki K, Kawasaki T, Nakashima M. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur J Pharmacol 1998; 345: 185-92.
• 20 Umemura K, Nishiyama H, Kikuchi S, Kondo K, Nakashima M. Inhibitory effect of a novel orally active GPIIb/IIIa inhibitor, Sc-54684A on intimal thickening in the guinea pig femoral artery. Thromb Haemost 1996; 76: 799-806.
• 21 Vandeplassche GM, Bernier M, Thone F, Borgers M, Kusama Y, Hearse DJ. Singlet oxygen and myocardial injury: Ultrastructual cytochemical and electrocardiographic consequences of photoactivation of rose bengal. J Mol Cell Cardiol 1990; 22: 287-301.